DYNAMICURE

Driven by science and passionate about advancing patient care, DynamiCure is translating potentially revolutionizing new insights on immuno-normalization into a pipeline of innovative antibody candidates with first-in-class and best-in-class potential. We are a team with broad and deep industry experience rapidly advancing multiple candidates towards the clinic... DynamiCure is translating breakthrough immuno-normalization insights into a pipeline of innovative therapeutic antibody candidates with first-in-class and best-in-class potential to benefit patients worldwide... Our lead program, DC-6001, aims to address the current limitations of today's most advanced cancer treatments by interfering with the CD93 pathway, a novel mechanism demonstrated to normalize malignant tumor vasculature. By binding to different epitopes of the CD93 receptor, we believe our development candidates have the potential to turn the tumor microenvironment (TME) from immunosuppressive to immunostimulatory..

Also known as: DynamiCure Biotechnology, DynamiCure Biotechnology, LLC

Primary location: Waltham United States